

BP in Dialysis: Results of a Pilot Study

Dana C. Miskulin,¹ Jennifer Gassman,² Ronald Schrader,³ Ambreen Gul,³ Manisha Jhamb,⁴ David W. Ploth,⁵ Lavinia Negrea,⁶ Raymond Y. Kwong,⁷ Andrew S. Levey,¹ Ajay K. Singh,⁷ Antonia Harford,^{3,8} Susan Paine,³ Cynthia Kendrick,² Mahboob Rahman,⁶ and Philip Zager^{3,8}

¹Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston, Massachusetts; ²Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio; ³Quality Management Department, Dialysis Clinic, Inc., Albuquerque, New Mexico; ⁴Renal-Electrolyte Division, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; ⁵Department of Medicine, Division of Nephrology, Medical University of South Carolina, Charleston, South Carolina; ⁶Division of Nephrology and Hypertension, Department of Medicine, University Hospitals Case Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio; ⁷Renal Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; and ⁸Division of Nephrology, Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, New Mexico

ABSTRACT

The optimal BP target for patients receiving hemodialysis is unknown. We randomized 126 hypertensive patients on hemodialysis to a standardized predialysis systolic BP of 110–140 mmHg (intensive arm) or 155–165 mmHg (standard arm). The primary objectives were to assess feasibility and safety and inform the design of a full-scale trial. A secondary objective was to assess changes in left ventricular mass. Median follow-up was 365 days. In the standard arm, the 2-week moving average systolic BP did not change significantly during the intervention period, but in the intensive arm, systolic BP decreased from 160 mmHg at baseline to 143 mmHg at 4.5 months. From months 4–12, the mean separation in systolic BP between arms was 12.9 mmHg. Four deaths occurred in the intensive arm and one death occurred in the standard arm. The incidence rate ratios for the intensive compared with the standard arm (95% confidence intervals) were 1.18 (0.40 to 3.33), 1.61 (0.87 to 2.97), and 3.09 (0.96 to 8.78) for major adverse cardiovascular events, hospitalizations, and vascular access thrombosis, respectively. The intensive and standard arms had similar median changes (95% confidence intervals) in left ventricular mass of -0.84 (-17.1 to 10.0) g and 1.4 (-11.6 to 10.4) g, respectively. Although we identified a possible safety signal, the small size and short duration of the trial prevent definitive conclusions. Considering the high risk for major adverse cardiovascular events in patients receiving hemodialysis, a full-scale trial is needed to assess potential benefits of intensive hypertension control in this population.

J Am Soc Nephrol 29: 307–316, 2018. doi: <https://doi.org/10.1681/ASN.2017020135>

The Kidney Disease Outcomes Quality Initiative guideline recommending a predialysis systolic BP (SBP) <140 mmHg in patients receiving hemodialysis (HD)¹ is on the basis of expert opinion.² Although hypertension control decreases mortality in the general population,³ observational studies in patients on HD have found increased mortality among those with $SBP \leq 140$ mmHg.^{4–9} Foley *et al.*¹⁰ and the Frequent Hemodialysis Network (FHN) Study Group reported that a decrease in SBP was associated with a decrease in left ventricular mass (LVM).¹¹ However, reducing predialysis SBP may increase the frequency of intradialytic hypotension (IDH),^{12,13}

major adverse cardiovascular events (MACE),^{14,15} and vascular access thromboses (VAT).¹⁶

In a meta-analysis of randomized, controlled trials (RCT) in patients receiving dialysis, antihypertensive therapy was associated with improved survival,

Received February 6, 2017. Accepted August 28, 2017.

Published online ahead of print. Publication date available at www.jasn.org.

Correspondence: Dr. Philip Zager, Dialysis Clinic, Inc., 1500 Indian School Road NE, Albuquerque, NM 87102. Email: pzager@unm.edu

Copyright © 2018 by the American Society of Nephrology

although the pooled decline in SBP was only 5 mmHg.¹⁷ In the Dry Weight Reduction in Hypertensive Hemodialysis Patients (DRIP) Study, a 1 kg decrease in mean estimated dry weight at 8 weeks was accompanied by a mean 6.6 mmHg decline in SBP.¹⁸ However, the short duration of the trial precluded assessing effects on clinical outcomes.

There is uncertainty regarding the optimal BP level and type of measurement. Predialysis SBP may be inferior to home BP measurements (HBPM) and ambulatory BP monitoring (ABPM) in predicting clinical outcomes.^{19,20} However, the long-term adherence of patients on HD with requirements for repeated HBPM and ABPM is unknown.

Recent trials in high-risk patients, without ESRD, present strong evidence of equipoise. In the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, targeting an SBP < 120 mmHg did not reduce MACE in patients with diabetes and was associated with increased hospitalization.²¹ In contrast, in the Systolic Blood Pressure Intervention Trial (SPRINT), conducted in high-risk nondiabetic patients, including those with an eGFR of 20–60 ml/min per 1.73 m², intensive control of SBP reduced all-cause mortality and MACE.²² ACCORD and SPRINT relied primarily upon measurements of clinic BP.

The primary objectives of the BP in Dialysis (BID) Pilot Study were to assess the feasibility and safety of treating hypertensive patients receiving HD to a standardized predialysis SBP of 110–140 mmHg (intensive arm) versus 155–165 mmHg (standard arm) and to inform the design of a full-scale RCT. Assessing changes in LVM was a secondary objective.

RESULTS

Participation Rates and Disposition

Approximately 45% of potentially eligible patients approached agreed to participate. A Consolidated Standards of Reporting Trials diagram depicts the flow of consented participants (Figure 1). We randomized 126 (45%) of the 281 participants who entered baseline, to intensive ($n=62$) and standard ($n=64$) treatment arms. The large number of dropouts during baseline reflected SBPs < 155 mmHg despite back-titration of antihypertensive medications, frequent IDH, or voluntary withdrawal (Supplemental Table 2). Median follow-up was 365 days (10th and 90th percentiles, 291 and 392 days). There were four deaths in the intensive and one in the standard arm, two renal transplants in each arm, and missing cardiac magnetic resonance imaging (MRI) in six and seven participants in the standard and intensive arms, respectively. The intervention was stopped for safety concerns in one participant in the standard arm (ischemic stroke) and one in the intensive arm (repeated hospitalizations for chest pain and uncontrolled hypertension).

Study Participants

Baseline demographic and clinical characteristics of randomized participants were similar across treatment arms (Table 1).

Significance Statement

The SPRINT trial demonstrated benefit of intensive control of blood pressure (BP) in high-risk, non-dialysis patients, but the optimal BP in hemodialysis patients is uncertain due to the lack of randomized clinical trial (RCT) data. We performed a pilot RCT of intensive versus standard BP control to assess the feasibility and safety of a full-scale RCT. During months 4–12 the average difference in systolic BP across arms was 12.9 mmHg. Although not powered for outcomes, we identified a potential safety signal: hospitalizations, vascular access thromboses, and intradialytic hypotension were more frequent in the intensive arm. These results support the need for a full-scale study to determine definitely the effects of intensive BP control on clinical outcomes in hemodialysis patients.

Mean age was 56.0 ± 12.8 years, 46.8% were black, 54.1% had diabetes as cause of ESRD, 72.2% were dialyzed with an arteriovenous fistula, and the average treatment time was 218.7 ± 27.8 minutes. Demographic and clinical characteristics of those randomized versus those enrolled but not randomized are shown (Supplemental Table 4). Age, race, and causes of ESRD were similar among randomized versus nonrandomized participants. Hispanics were more common among randomized participants.

Adherence with BP Measurements

Tables summarizing adherence with prescribed standardized dialysis unit BP measurements (SDUBPM) and HBPM are included in Supplemental Tables 5 and 7. We obtained ≥ 4 SDUBPM in 97%, 91%, 86%, and 75% of participants in months 1, 4, 8, and 12, respectively. However, in the same months, we obtained ≥ 1 HBPM in only 82%, 73%, 68%, and 62% and ≥ 4 HBPM in 36%, 33%, 25%, and 22%. We obtained ABPM in only 32%, 29%, 28%, and 58% of participants in quarters 1, 2, 3, and 4, respectively.

SBP

At baseline, 6, and 12 months, mean SBP in the intensive and standard arms was 159.7, 144.2, and 146.4 mmHg, and 159.9, 156.2, and 156.6 mmHg, respectively. Figure 2A shows the fitted values for 2-week moving averages of SDUBPM with 95% confidence intervals (95% CI), computed using a restricted cubic spline model. In the standard arm, the 2-week moving average SBP did not change significantly during the intervention period (horizontal line fits within the confidence band). In contrast, in the intensive arm the fitted 2-week average SBP decreased from 160 mmHg at baseline to 143 mmHg at 4.5 months. Separation in SBP between the arms was maintained from 2 months until the end of the study. Separation was greatest (14 mmHg) at 4.5 months. During months 4–12, mean separation in SBP between arms was 12.9 mmHg. The overall pattern of the fitted values for 2-week moving averages of SDUBPM and morning home SBP was similar (Figure 2B). Overall, the predialysis SBP was 6.1 ± 0.7 mmHg higher than the home SBP. We estimated within-subject SDs for SBP obtained from SDUBPM immediately




Figure 1. Consort diagram showing participant flow from enrollment to randomization, follow-up, and analysis. F12, month 12 post randomization; LV, left ventricular; SDUSBP, standardized dialysis unit systolic blood pressure.

before the midweek dialysis and HBPM taken the following morning using a linear mixed model in SAS 9.4. We obtained estimates of 14.3 and 16.9 mmHg for within-subject SDs for SBP obtained in the dialysis unit and at home, respectively, using a likelihood ratio test ($P < 0.001$) as described by Rhorscheib *et al.*²³

The mean number of antihypertensive medications, by month, in each arm is shown in Figure 2C. The number of antihypertensive medications was greater in the intensive versus standard arm at baseline (2.9 versus 2.4), 6 months (3.5 versus 2.5), and 12 months (3.5 versus 2.5). The percentage of participants who were prescribed angiotensin converting enzyme inhibitors or angiotensin receptor blockers was higher in the intensive versus standard treatment arms (Figure 2C).

Postdialysis Weight and Interdialytic Weight Gain by Treatment Arm

During the intervention, postdialysis weight, expressed as least square means and 95% CI, decreased by 1.05 (95% CI, -1.55 to -0.55 ; $P < 0.001$) kg in the standard arm but increased by 1.13 (95% CI, 0.60 to 1.66; $P < 0.001$) kg in the intensive arm. Interdialytic weight gain after a 2-day interval decreased by 0.20 (95% CI, -0.30 to -0.10 ; $P < 0.001$) kg and by 0.25 (95% CI, -0.35 to -0.15 ; $P < 0.001$) kg in the intensive and

standard arms, respectively. After a 3-day interval, interdialytic weight gain decreased by 0.10 (95% CI, -0.23 to 0.04; $P = 0.16$) kg and 0.19 (95% CI, -0.32 to -0.06 ; $P = 0.003$) kg in the intensive and standard arms, respectively. There were no significant changes in treatment time in either arm.

Safety Outcomes

There were four deaths in the intensive arm: one acute myocardial infarction, one cardiac arrhythmia, one vascular access hemorrhage, and one lung cancer. There was one death in the standard arm which was attributed to a combination of stroke, acute myocardial infarction, and heart failure. The incidence rate ratios (IRR) were 1.18 (95% CI, 0.40 to 3.33; $P = 0.78$); 1.61 (95% CI, 0.87 to 2.97; $P = 0.13$); 3.09 (95% CI, 0.96 to 8.78; $P = 0.06$); and 0.90 (95% CI, 0.51 to 1.58; $P = 0.72$) for MACE, all-cause hospitalizations, VATs, and emergency room visits (Table 2). The hazard ratios (HR) for time to first and to recurrent events are shown (Table 2).

Intradialytic Events and Symptoms

The frequency of IDH requiring intervention was similar in the intensive versus standard arm (IRR, 1.29; 95% CI, 0.86 to 1.94; $P = 0.22$). The IRR and HR for other intradialytic events are summarized in Table 3. The IRRs for any intradialytic event

Table 1. Baseline characteristics of participants

Characteristic	Intensive Treatment Arm (n=62) n (%) or mean±SD	Standard Treatment Arm (n=64) n (%) or mean±SD	P Value
Age, yr	56.7±14.5	55.3±10.8	0.55
Men	32 (51.6)	39 (60.9)	0.37
Race			0.85
Native American, Aboriginal Canadian/Alaskan	4 (6.5)	2 (3.1)	
Asian	4 (6.5)	4 (6.3)	
Black, African	30 (48.4)	29 (45.3)	
White	22 (35.5)	28 (43.8)	
More than one race, part Native American	1 (1.6)		
Unknown or not reported	1 (1.6)	1 (1.6)	
Hispanic ethnicity	21 (33.9)	23 (35.9)	0.85
Cause of ESRD			0.68
Diabetic nephropathy	30 (50.9)	36 (57.1)	
Hypertensive nephrosclerosis	22 (37.3)	17 (27.0)	
GN	4 (6.8)	6 (9.5)	
Other	3 (5.1)	4 (6.4)	
Vascular access			0.77
Arteriovenous graft	11 (17.7)	11 (17.2)	
Arteriovenous fistula	46 (74.2)	45 (70.3)	
Central venous catheter	5 (8.1)	8 (12.5)	
Years on dialysis (from most recent dialysis start)	3.1±2.4	3.5±2.8	0.39
BMI, kg/m ²	28.1±7.0	27.1±5.8	0.38
Last baseline 2 wk running mean SBP	161.1±9.8	160.5±11.9	0.76
Last baseline 2 wk running mean DBP	79.5±12.2	82.1±12.3	0.24
Treatment time, min	216.8±30.2	220.5±25.4	0.46
FACIT score	30.8±12.9	30.0±12.8	0.76
Charlson index	3.3±1.0	3.3±1.0	0.89
Number of antihypertensive medications	2.9±1.4	2.4±1.1	0.03
History of myocardial infarction	4 (6.5)	5 (7.8)	1.00
History of congestive heart failure	9 (14.5)	9 (14.1)	1.00
History of CVA	4 (6.5)	3 (4.7)	0.72
History of atrial fibrillation	2 (3.2)	1 (1.6)	0.62
LVH (n=102)	42 (87.5)	43 (79.6)	0.43

P values for race, cause of ESRD, and arteriovenous access types are from chi-squared test. BMI, body mass index; DBP, diastolic blood pressure; CVA, cerebrovascular accident.

did not differ significantly across treatment arms. However, the HR for recurring events of hypotension, cramps, and nausea/vomiting revealed significant increased risks in the intensive arm.

LVM

At baseline, 87.5% and 79.6% of participants in the intensive and standard arms, respectively, had left ventricular hypertrophy (LVH) by LVM.²⁴ In the intensive arm, median LVM, excluding papillary muscle, decreased from baseline 149.5 (95% CI, 115.0 to 184.3) g to 133.2 (95% CI, 110.2 to 168.7) g at month 12 (Table 4). In the standard arm, median LVM increased slightly from baseline 143.8 (95% CI, 120.4 to 176.8) g to month 12, 149.9 (95% CI, 126.8 to 176.0) g. The median differences from baseline to month 12 in the intensive arm −0.84 (95% CI, −17.1 to 10.0) g versus the standard arm 1.4 (95% CI −11.6 to 10.4) g were similar ($P=0.43$).

Health-Related Quality of Life

There were no differences in baseline values and changes in the Functional Assessment of Chronic Illness Therapy (FACIT)

fatigue scores across treatment arms. Recovery times at baseline and follow-up were similar in each treatment arm (Supplemental Table 8). The physical and mental component scores, respectively, on the Short Form-36 (SF-36) did not differ across treatment arms at baseline or on the last administration (Supplemental Table 9).

DISCUSSION

The BID Pilot demonstrated the feasibility of recruiting and retaining hypertensive patients receiving HD in an RCT of intensive versus standard control of SBP. Similar to ACCORD²¹ and SPRINT,²² the achieved average SBP in the intensive arm was slightly above the target. However, we achieved a sustained ≥ 10 mmHg separation in both predialysis and morning home SBP, the magnitude required to detect a 20% relative reduction in MACE.²⁵ The magnitude of the separation in SBP across treatment arms was similar to that in previous




Figure 2. Standardized dialysis unit and home SBP and mean number of antihypertensive medications. (A) Fitted values for 2-week moving averages of SBP measured in the dialysis unit. (B) Fitted values for 2-week moving averages of SBP measured at home. (C) Mean number of antihypertensive medications throughout the intervention period.

trials. The African American Study of Kidney Disease achieved an average (SD) BP 128/78 (12/8) mmHg in the intensive versus 141/85 (12/7) mmHg in the standard arm.^{26,27} DRIP, an RCT of aggressive ultrafiltration versus usual care, achieved a 6.6 (95% CI, 12.2 to 1.0 mmHg; $P=0.02$) mmHg reduction in SBP at 8 weeks among patients randomized to aggressive ultrafiltration.¹⁸ In the FHN Trial, the decrease in mean SBP from baseline to 12 months was 10.1 (95% CI, 6.0 to 14.3) mmHg greater in the six versus three times weekly HD arm.¹⁰

BID encouraged site investigators to challenge estimated dry weight as the initial step in reducing SBP. Because many participants were intolerant to or refused these challenges, changes in antihypertensive medications were mainly responsible for achieving separation in SBP across treatment arms. This is similar to the experience in an RCT of atenolol versus lisinopril in which mean postdialysis weight increased by 0.9 kg and decreased by 1.5 kg in the atenolol and lisinopril arms, respectively.²⁸ However, in DRIP

there was a -1 (95% CI, -1.6 to -0.5) kg change in postdialysis weight at 8 weeks in the aggressive ultrafiltration arm, which was the sole intervention.¹⁸ Because DRIP lasted only 8 weeks it did not test long-term feasibility of aggressive ultrafiltration.

Although volume is undoubtedly important, the pathogenesis of hypertension in patients on HD is multifactorial. A German study of 500 hypertensive patients receiving HD used bioimpedance to estimate extracellular volume. Less than 50% of hypertensive participants had evidence of volume expansion.²⁹ In a recent observational study of patients receiving HD treated in facilities operated by Fresenius Medical Care, sustained fluid overload was strongly associated with increased mortality across BP categories.³⁰ However, because the study was observational it did not establish causation. Several studies have shown that aggressive ultrafiltration is associated with increased frequency of IDH,³¹ VAT,¹⁶ loss of residual renal function,³² and increased mortality.^{33–35}

As in ACCORD²¹ and SPRINT,²² the rate of serious adverse events (SAEs) was higher in the intensive versus the standard treatment arm. BID identified a possible safety signal because deaths, all-cause hospitalizations, and VATs were more frequent in the intensive arm. However, there were no significant differences in the number of patients hospitalized or experiencing VATs. The frequency of MACE or emergency room (ER) visits, respectively, was similar across treatment arms. Overall, hospitalizations in BID were not more frequent than reported by the US Renal Data Systems (USRDS).³⁶ The frequency of IDH was higher in the intensive versus standard treatment arm. Nevertheless, the frequency of IDH in the intensive arm (3.7%) was lower than in the baseline period of the Hemodialysis (HEMO) study (11.3%),¹³ a large United States dialysis provider organization (9.7%),¹³ and the conventional (10.9%) and frequent (13.6%) arms of FHN.¹⁰ VATs were more frequent in the intensive versus the standard arm. These results are consistent with data from a subset of HEMO participants, in which low predialysis SBP and frequent IDH were associated with an increase in VAT.¹⁶ In BID, VATs were less common than in the control arm of contemporary prospective trials for arteriovenous grafts³⁷ and fistulas.³⁸ However, the increase in VATs in the intensive arm of BID and the daily arm of FHN speaks to the need to ascertain the risk-benefit ratios of these interventions in RCTs powered for all-cause mortality and MACE.

In BID, LVM tended to decrease in the intensive arm and increase in the standard arm but these differences did not attain statistical significance. Although we were underpowered for this outcome, it is possible that targeting a lower SBP may not reduce LVM in hypertensive patients receiving HD dialyzed thrice weekly. Nevertheless, multiple studies have shown that decreases in dialysis unit BP are associated with decreases in LVM.^{10,11,39}

We chose predialysis SDUBPM rather than HBPM to guide therapy, in anticipation that adherence with HBPM would be low. Some investigators have postulated that HBPM and ABPM are superior to predialysis BP in predicting LVH.^{19,20} However,

Table 2. Hospitalizations and VAT

Event	No. Events/No. Subjects		IRR (95% CI)	P Value	HR ^b of Time to First Event (95% CI)	P Value	HR ^c of Recurrent Events (95% CI)	P Value
	Incidence Rate ^a per Patient Year (95% CI)							
	Intensive Arm (n=62)	Standard Arm (n=64)						
MACE ^d	11/10 0.20 (0.09 to 0.41)	10/6 0.17 (0.08 to 0.37)	1.18 (0.40 to 3.33)	0.78	1.76 (0.64 to 4.85)	0.27	0.89 (0.30 to 2.66)	0.84
Hospitalization	85/29 1.51 (0.99 to 2.30)	53/25 0.94 (0.60 to 1.46)	1.61 (0.87 to 2.97)	0.13	1.29 (0.76 to 2.21)	0.35	1.66 (1.18 to 2.34)	0.004
VAT	19/10 0.34 (0.18 to 0.66)	7/7 0.11 (0.05 to 0.28)	3.09 (0.96 to 8.78)	0.06	1.54 (0.59 to 4.04)	0.38	2.80 (1.18 to 6.66)	0.020
ER visit	50/30 0.89 (0.59 to 1.34)	55/27 0.99 (0.67 to 1.46)	0.90 (0.51 to 1.58)	0.72	1.24 (0.74 to 2.09)	0.42	0.94 (0.64 to 1.38)	0.74

^aCalculated using negative binomial regression.^bCalculated using Cox proportional hazards regression.^cCalculated using Anderson–Gill method in Cox proportional hazards regression.^dMACE defined as fatal or nonfatal myocardial infarction, stroke, or hospitalization for congestive heart failure.

the majority of these reports compared only 2 weeks of predialysis BP, 1 week of HBPM, and a single 44-hour ABPM. Moreover, there was considerable overlap in the 95% CI of the area under the receiver operator characteristic curves for predialysis BP, HBPM, and ABPM.¹⁹ Conion *et al.*⁴⁰ and Zoccali *et al.*³⁹ reported that multiple BP readings averaged over a month are as good as ABPM in predicting an increase in LVM.

Strengths and Limitations

BID has several important strengths. It was the first RCT to randomize patients receiving HD to different predialysis SBP targets. Participants were demographically diverse and treated in for-profit and not-for-profit facilities. BP measurements were made in accord with American Heart Association (AHA) guidelines. A National Institutes Health (NIH)–appointed Review Panel and a Data Safety Monitoring Board

reviewed the study before its start. An experienced Outcomes Committee (A.S.L. and A.K.S.) adjudicated outcomes. The main limitations relate to the small size and short duration, which constrained statistical power and generalizability, and the lack of an objective tool for assessing volume. Although some may argue that the use of SDUBPM instead of HBPM or ABPM to drive therapy is a limitation,^{19,20} the enhanced adherence with SDUBPM likely overrides this potential limitation. The mean age of participants (56.0 years) was slightly lower than that of prevalent patients in the USRDS 2016 Annual Data Report (59.4 years);^{41–43} 25% were ≥65 years of age. We did not perform pill counts or HPLC of antihypertensive medication metabolites.^{44,45}

Informing the Design of a Full-Scale Trial

In a full-scale trial, it may be necessary to protocolize challenges to postdialysis weights, including use of frequent small decrements;

Table 3. Intradialytic events

Events	No. Events/No. Subjects ^a		IRR (95% CI)	P Value	HR ^b of Time to First Event (95% CI)	P Value	HR ^c of Recurrent Events (95% CI)	P Value
	per 100 Treatments (95% CI)							
	Intensive Arm (n=62)	Standard Arm (n=64)						
SBP<90 mmHg	332/39 3.67 (2.53 to 5.31)	264/45 2.69 (1.85 to 3.91)	1.36 (0.80 to 2.31)	0.25	0.88 (0.57 to 1.35)	0.56	1.30 (1.10 to 1.52)	0.002
Cramps	641/55 6.74 (5.05 to 8.96)	571/51 5.87 (4.42 to 7.82)	1.15 (0.77 to 1.72)	0.51	1.19 (0.81 to 1.75)	0.37	1.16 (1.04 to 1.30)	0.01
Nausea±vomiting	90/25 0.98 (0.61 to 1.57)	66/29 0.73 (0.44 to 1.17)	1.35 (0.70 to 2.63)	0.37	0.89 (0.52 to 1.53)	0.68	1.41 (1.02 to 1.94)	0.04
Dizziness	110/24 1.15 (0.66 to 2.01)	126/23 1.31 (0.75 to 2.27)	0.88 (0.40 to 1.95)	0.76	1.00 (0.56 to 1.78)	>0.99	0.92 (0.71 to 1.19)	0.50
Dyspnea	27/12 0.28 (0.12 to 0.68)	56/11 0.66 (0.28 to 1.50)	0.44 (0.13 to 1.45)	0.18	1.13 (0.50 to 2.57)	0.77	0.50 (0.31 to 0.79)	0.003
Chest pain	11/7 0.12 (0.05 to 0.26)	9/7 0.09 (0.05 to 0.21)	1.27 (0.40 to 4.01)	0.69	1.06 (0.37 to 3.03)	0.91	1.26 (0.52 to 3.04)	0.61
Loss of consciousness	4/4 0.05 (0.02 to 0.12)	1/1 0.00 (0.00 to 0.07)	4.15 (0.46 to 37.12)	0.20	4.18 (0.47 to 37.43)	0.20	4.10 (0.46 to 36.64)	0.21
Seizure	2/1 0.02 (0.00 to 0.19)	1/1 0.00 (0.00 to 0.14)	2.05 (0.08 to 55.05)	0.67	1.05 (0.07 to 16.84)	0.97	2.08 (0.19 to 22.95)	0.55

Includes all events, regardless of whether an intervention was done. Referent group: Standard treatment arm.

^aCalculated using negative binomial regression^bCalculated using Cox proportional hazards regression^cCalculated using Anderson–Gill method in Cox proportional hazards regression

Table 4. Effects of intensive versus standard SBP goal on LVM

Variable	Intensive Arm (n=48)	Standard Arm (n=54)	P Value of Differences Across Arms
Baseline median (IQR) LVM (g/m)	149.5 (115.0, 184.3)	143.8 (120.4, 176.8)	0.95
F12 median (IQR) LVM (g/m)	133.2 (110.2, 168.7)	149.9 (126.8, 176.0)	0.19
Median difference (IQR) (g/m ²) baseline minus month 12	−0.84 (−17.1, 10.0)	1.4 (−11.6, 10.4)	0.43

IQR, interquartile range; F12, study visit in month 12 post randomization.

repeated measurements of volume *via* a practical, accurate, and reliable method;³⁰ and participant agreement to adhere to dialysis prescriptions. Despite their putative advantages, use of HBPM or ABPM to drive therapy would require innovative solutions to ensure adequate adherence. Although SDUBPM added approximately 8 minutes to the treatment time, which some staff and participants found burdensome, adherence was excellent and indicates it could be used in a full-scale trial. Vascular access monitoring should be incorporated into a full-scale trial to minimize risk for VAT. The use of cooled dialysate may be considered to decrease the risk for IDH and VAT.

BID demonstrated the feasibility and safety of conducting a full-scale RCT to test the hypothesis that intensive SBP lowering in patients receiving HD reduces MACEs and all-cause mortality. However, the pilot study did identify a potential safety signal. Although the deaths in the intensive arm did not appear to be protocol related, all-cause hospitalizations, VAT, and IDH, analyzed as recurrent events, were increased in the intensive arm. Given the small size and short duration of BID, these findings represent a safety signal, not a definitive result. Given the high risk for adverse cardiovascular events in patients receiving HD and the potential benefits of intensive SBP lowering observed in SPRINT, conducting a large-scale trial is warranted.

CONCISE METHODS

The study protocol has been previously described in Gul *et al.*⁴⁶

The Study Protocol is currently available at: <http://qhsapps.ccf.org/bid/protocol/Protocol.pdf> and will become available on the National Institute of Diabetes and Digestive and Kidney Diseases repository website.

Study Population

Each site's institutional review board approved the study. Our goal was to recruit 120 participants from five geographic hubs, which included dialysis units operated by Dialysis Clinic, Inc. (DCI), Centers for Dialysis Care, and DaVita. Eligibility criteria included ≥ 18 years of age, treatment with HD for ≥ 3 months, upper arm suitable for measuring BP, and a 2-week average predialysis SBP ≥ 155 mmHg. Exclusion criteria included unscheduled dialysis treatments for congestive heart failure and IDH requiring hospitalization in the 3 months before enrollment.⁴⁶

Baseline Period

Antihypertensive medications were sometimes reduced (back-titrated) to achieve a 2-week average predialysis SBP ≥ 155 mmHg.

Comorbidity was classified using the Charlson Index.⁴⁷ The FACIT⁴⁸ and the recovery question were administered.⁴⁹ LVM was measured using MRI. We used web-based randomization with random-sized blocks and stratification by geographic site to ensure unpredictable treatment allocation and balance within sites.

Study Visits

At each study visit, participants were asked if they had a recent hospitalization, ER visit, VAT, or IDH. VAT was defined by the inability to use the access for dialysis due to thrombosis with an urgent need for intervention to restore flow. IDH was defined as an intradialytic SBP < 90 mmHg.

BP Control

In planning the study, we were aware of the putative superiority of HBPM and ABPM compared with predialysis BP for predicting outcomes including LVH.^{19,20} However, the primary objectives of the BID pilot were to assess the safety, feasibility, and inform the design of a full-scale trial to determine optimal dialysis unit SBP. Also, there is considerable evidence that dialysis unit SBP can predict changes in LVM. Because we had significant concerns about adherence with HBPM and ABPM during a 1-year intervention, the BID investigators and DSMB decided that the possible slightly stronger predictive value of HBPM and ABPM versus SDUBPM would be offset by poorer adherence.

Standardized predialysis BP was measured in accord with AHA guidelines.⁵⁰ Although we used SDUBPM to drive therapy, the study protocol included morning and afternoon HBPM the day after each midweek dialysis⁴⁶ and (in four geographic hubs) quarterly ABPM.⁴⁶ We encouraged site investigators to challenge postdialysis weights as the initial step in attaining the assigned target SBP. This was followed by addition of antihypertensive agents. Blockade of the renin-angiotensin system was the preferred first-line antihypertensive drug therapy, unless there was an indication for a β -adrenergic blocker. The DCI pharmacy provided all study medications.

Assessing Outcomes

We reviewed discharge summaries and coded primary diagnoses using a study-specific checklist. The Outcomes Committee adjudicated all deaths, MACE, VATs, and a random sample of noncardiovascular SAEs. The NIH-appointed Data and Safety Monitoring Board reviewed all SAEs annually. Baseline and 12-month cardiac MRIs were read side-by-side, in blinded fashion, by a cardiologist using a standardized protocol, at Brigham and Women's Hospital (Supplemental Appendix 5). We assessed health-related quality of life by administering the FACIT, recovery question, and SF-36 at baseline and at the end of the intervention.

Statistical Analyses

Feasibility was assessed by number of participants randomized, separation in 2-week running average of predialysis SBP between arms, and participant retention. Prespecified safety outcomes included deaths, all-cause hospitalizations, MACE, VAT, and IDH. We calculated incidence rates with corresponding 95% CIs for all-cause hospitalizations, MACE, and ER visits. Incidence rates were calculated by negative binomial regression from the MASS⁵¹ package in R⁵² after using Akaike information criterion and Vuong's test from the PSCI⁵³ package to eliminate Poisson regression and zero-inflated versions of Poisson and negative binomial regression. We tested for differences across treatment arms by computing HR and corresponding 95% CI with proportional hazards regression for time to first event and for recurring events (Anderson–Gill model).

To assess the longitudinal trends of standardized SBP in each treatment arm we examined 2-week moving averages for each participant. We used a linear mixed model with autoregressive error structure to model trends in SBP moving averages throughout the study. Time was fit using restricted cubic splines to allow for nonlinear trends in the data.⁵⁴ To assess changes in LVM by arm, we specified a Wilcoxon–Mann–Whitney rank sum test before testing because the data were skewed. We recognized that the small size of the trial severely constrained our power to detect a difference between arms for change in LVM. We had only 80% power to detect a ≥ 21.5 g difference, which was almost twice the difference observed in the Daily Trial in FHN.¹⁰ Analyses were performed using SAS 9.4 (SAS Institute, Cary, NC) and R Core Team 2016.52.

For the SF-36 analysis, we compared between-group mean changes in scores from baseline to month 12 for the physical component summary scores and mental component summary scores using linear mixed effects models with unstructured covariance matrix incorporating baseline and 12-month scores for each metric. We adjusted for baseline score, clinical center, and the interactions of these factors with treatment time. ClinicalTrials.gov Identifier: NCT01421771.

ACKNOWLEDGMENTS

Supported by National Institute of Diabetes and Digestive and Kidney Diseases (R01DK083424) and Dialysis Clinic, Inc.

DISCLOSURES

None.

REFERENCES

1. K/DOQI Workgroup: K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. *Am J Kidney Dis* 45[Suppl 3]: S1–S153, 2005
2. Kjeldsen SE, Hedner T, Jamerson K, Julius S, Haley WE, Zabalgoitia M, Butt AR, Rahman SN, Hansson L: Hypertension optimal treatment (HOT) study: Home blood pressure in treated hypertensive subjects. *Hypertension* 31: 1014–1020, 1998
3. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration: Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet* 360: 1903–1913, 2002
4. Hannedouche T, Roth H, Krummel T, London GM, Jean G, Bouchet JL, Drüeke TB, Fouque D; French Observatory: Multiphasic effects of blood pressure on survival in hemodialysis patients. *Kidney Int* 90: 674–684, 2016
5. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, Greenland S, Kopple JD: Reverse epidemiology of hypertension and cardiovascular death in the hemodialysis population: The 58th annual fall conference and scientific sessions. *Hypertension* 45: 811–817, 2005
6. Port FK, Hulbert-Shearon TE, Wolfe RA, Bloembergen WE, Golper TA, Agodoa LY, Young EW: Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. *Am J Kidney Dis* 33: 507–517, 1999
7. Robinson BM, Tong L, Zhang J, Wolfe RA, Goodkin DA, Greenwood RN, Kerr PG, Morgenstern H, Li Y, Pisoni RL, Saran R, Tentori F, Akizawa T, Fukuhara S, Port FK: Blood pressure levels and mortality risk among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. *Kidney Int* 82: 570–580, 2012
8. Tentori F, Hunt WC, Rohrscheib M, Zhu M, Stidley CA, Servilla K, Miskulin D, Meyer KB, Bedrick EJ, Johnson HK, Zager PG: Which targets in clinical practice guidelines are associated with improved survival in a large dialysis organization? *J Am Soc Nephrol* 18: 2377–2384, 2007
9. Zager PG, Nikolic J, Brown RH, Campbell MA, Hunt WC, Peterson D, Van Stone J, Levey A, Meyer KB, Klag MJ, Johnson HK, Clark E, Sadler JH, Teredesai P: “U” curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. *Kidney Int* 54: 561–569, 1998
10. Chertow GM, Levin NW, Beck GJ, Depner TA, Eggers PW, Gassman JJ, Gorodetskaya I, Greene T, James S, Larive B, Lindsay RM, Mehta RL, Miller B, Ornt DB, Rajagopalan S, Rastogi A, Rocco MV, Schiller B, Sergeyeva O, Schulman G, Ting GO, Unruh ML, Star RA, Kliger AS; FHN Trial Group: In-center hemodialysis six times per week versus three times per week. *N Engl J Med* 363: 2287–2300, 2010
11. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. *Kidney Int* 49: 1379–1385, 1996
12. Daugirdas JT: Measuring intradialytic hypotension to improve quality of care. *J Am Soc Nephrol* 26: 512–514, 2015
13. Flythe JE, Xue H, Lynch KE, Curhan GC, Brunelli SM: Association of mortality risk with various definitions of intradialytic hypotension. *J Am Soc Nephrol* 26: 724–734, 2015
14. Sands JJ, Usvyat LA, Sullivan T, Segal JH, Zabetakis P, Kotanko P, Maddux FW, Diaz-Buxo JA: Intradialytic hypotension: Frequency, sources of variation and correlation with clinical outcome. *Hemodial Int* 18: 415–422, 2014
15. Stefánsson BV, Brunelli SM, Cabrera C, Rosenbaum D, Anum E, Ramakrishnan K, Jensen DE, Ståhlhammar NO: Intradialytic hypotension and risk of cardiovascular disease. *Clin J Am Soc Nephrol* 9: 2124–2132, 2014
16. Chang TI, Paik J, Greene T, Desai M, Bech F, Cheung AK, Chertow GM: Intradialytic hypotension and vascular access thrombosis. *J Am Soc Nephrol* 22: 1526–1533, 2011
17. Heerspink HJ, Ninomiya T, Zoungas S, de Zeeuw D, Grobbee DE, Jardine MJ, Gallagher M, Roberts MA, Cass A, Neal B, Perkovic V: Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: A systematic review and meta-analysis of randomised controlled trials. *Lancet* 373: 1009–1015, 2009
18. Agarwal R, Alborzi P, Satyan S, Light RP: Dry-weight reduction in hypertensive hemodialysis patients (DRIP): A randomized, controlled trial. *Hypertension* 53: 500–507, 2009
19. Agarwal R, Andersen MJ, Light RP: Location not quantity of blood pressure measurements predicts mortality in hemodialysis patients. *Am J Nephrol* 28: 210–217, 2008

20. Alborzi P, Patel N, Agarwal R: Home blood pressures are of greater prognostic value than hemodialysis unit recordings. *Clin J Am Soc Nephrol* 2: 1228–1234, 2007
21. Cushman WC, Evans GW, Byington RP, Goff DC Jr., Grimm RH Jr., Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F; ACCORD Study Group: Effects of intensive blood-pressure control in type 2 diabetes mellitus. *N Engl J Med* 362: 1575–1585, 2010
22. Wright JT Jr., Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr., Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT; SPRINT Research Group: A randomized trial of intensive versus standard blood-pressure control. *N Engl J Med* 373: 2103–2116, 2015
23. Rohrscheib MR, Myers OB, Servilla KS, Adams CD, Miskulin D, Bedrick EJ, Hunt WC, Lindsey DE, Gabaldon D, Zager PG; DCI Medical Directors: Age-related blood pressure patterns and blood pressure variability among hemodialysis patients. *Clin J Am Soc Nephrol* 3: 1407–1414, 2008
24. Kawel-Boehm N, Maceira A, Valsangiacomo-Buechel ER, Vogel-Claussen J, Turkbey EB, Williams R, Plein S, Tee M, Eng J, Bluemke DA: Normal values for cardiovascular magnetic resonance in adults and children. *J Cardiovasc Magn Reson* 17: 29, 2015
25. Cushman WC, Grimm RH Jr., Cutler JA, Evans GW, Capes S, Corson MA, Sadler LS, Alderman MH, Peterson K, Bertoni A, Basile JN; ACCORD Study Group: Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. *Am J Cardiol* 99[12A]: 44i–55i, 2007
26. Appel LJ, Wright JT Jr., Greene T, Agodoa LY, Astor BC, Bakris GL, Cleveland WH, Charleston J, Contreras G, Faulkner ML, Gabbai FB, Gassman JJ, Hebert LA, Jamerson KA, Kopple JD, Kusek JW, Lash JP, Lea JP, Lewis JB, Lipkowitz MS, Massry SG, Miller ER, Norris K, Phillips RA, Pogue VA, Randall OS, Rostand SG, Smogorzewski MJ, Toto RD, Wang X; AASK Collaborative Research Group: Intensive blood-pressure control in hypertensive chronic kidney disease. *N Engl J Med* 363: 918–929, 2010
27. Wright JT Jr., Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glasscock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG; African American Study of Kidney Disease and Hypertension Study Group: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. *JAMA* 288: 2421–2431, 2002
28. Agarwal R, Sinha AD, Pappas MK, Abraham TN, Tegegne GG: Hypertension in hemodialysis patients treated with atenolol or lisinopril: A randomized controlled trial. *Nephrol Dial Transplant* 29: 672–681, 2014
29. Wabel P, Moissl U, Chamney P, Jirka T, Machek P, Ponce P, Taborsky P, Tetta C, Velasco N, Vlasak J, Zaluska W, Wizemann V: Towards improved cardiovascular management: The necessity of combining blood pressure and fluid overload. *Nephrol Dial Transplant* 23: 2965–2971, 2008
30. Zoccali C, Moissl U, Chazot C, Mallamaci F, Tripepi G, Arkoossy O, Wabel P, Stuard S: Chronic fluid overload and mortality in ESRD. *J Am Soc Nephrol* 28: 2491–2497, 2017
31. Garg N, Fissell WH: Intradialytic hypotension: A case for going slow and looking carefully. *Nephrol Dial Transplant* 28: 247–249, 2013
32. Mathew AT, Fishbane S, Obi Y, Kalantar-Zadeh K: Preservation of residual kidney function in hemodialysis patients: Reviving an old concept. *Kidney Int* 90: 262–271, 2016
33. Assimon MM, Flythe JE: Variability may be the “Law of Life,” but blood pressure variability may forebode a shorter life. *Am J Kidney Dis* 67: 830–833, 2016
34. Flythe JE, Kimmel SE, Brunelli SM: Rapid fluid removal during dialysis is associated with cardiovascular morbidity and mortality. *Kidney Int* 79: 250–257, 2011
35. Flythe JE, Brookhart MA: Fluid management: The challenge of defining standards of care. *Clin J Am Soc Nephrol* 9: 2033–2035, 2014
36. United States Renal Data System: 2015 USRDS annual data report: Epidemiology of kidney disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2015
37. Lok CE, Moist L, Hemmelgarn BR, Tonelli M, Vazquez MA, Dorval M, Oliver M, Donnelly S, Allon M, Stanley K; Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study Group: Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: A randomized controlled trial. *JAMA* 307: 1809–1816, 2012
38. Polkinghorne KR, Lau KK, Saunderson A, Atkins RC, Kerr PG: Does monthly native arteriovenous fistula blood-flow surveillance detect significant stenosis—a randomized controlled trial. *Nephrol Dial Transplant* 21: 2498–2506, 2006
39. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cottini E, Giaccone G, Malatino L: Prediction of left ventricular geometry by clinic, pre-dialysis and 24-h ambulatory BP monitoring in hemodialysis patients: CREED investigators. *J Hypertens* 17: 1751–1758, 1999
40. Conion PJ, Walshe JJ, Heinle SK, Minda S, Krucoff M, Schwab SJ: Predialysis systolic blood pressure correlates strongly with mean 24-hour systolic blood pressure and left ventricular mass in stable hemodialysis patients. *J Am Soc Nephrol* 7: 2658–2663, 1996
41. Chan CT, Greene T, Chertow GM, Kliger AS, Stokes JB, Beck GJ, Daugirdas JT, Kotanko P, Larive B, Levin NW, Mehta RL, Rocco M, Sanz J, Schiller BM, Yang PC, Rajagopalan S; Frequent Hemodialysis Network (FHN) Trial Group: Determinants of left ventricular mass in patients on hemodialysis: Frequent Hemodialysis Network (FHN) trials. *Circ Cardiovasc Imaging* 5: 251–261, 2012
42. Kotanko P, Garg AX, Depner T, Pierratos A, Chan CT, Levin NW, Greene T, Larive B, Beck GJ, Gassman J, Kliger AS, Stokes JB; FHN Trial Group: Effects of frequent hemodialysis on blood pressure: Results from the randomized frequent hemodialysis network trials. *Hemodial Int* 19: 386–401, 2015
43. United States Renal Data System: 2016 USRDS annual data report: Epidemiology of kidney disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2016
44. Sternlicht H, Bakris GL: Resistant hypertension: A refractory disease or refractory patient. *Hypertension* 69: 582–583, 2017
45. Tomaszewski M, White C, Patel P, Masca N, Damani R, Hepworth J, Samani NJ, Gupta P, Madira W, Stanley A, Williams B: High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. *Heart* 100: 855–861, 2014
46. Gul A, Miskulin D, Gassman J, Harford A, Horowitz B, Chen J, Paine S, Bedrick E, Kusek JW, Unruh M, Zager P; BID Pilot Study Investigators: Design of the blood pressure goals in dialysis pilot study. *Am J Med Sci* 347: 125–130, 2014
47. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. *J Chronic Dis* 40: 373–383, 1987
48. Cella DF, Tulskey DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J: The functional assessment of cancer therapy scale: Development and validation of the general measure. *J Clin Oncol* 11: 570–579, 1993
49. Lindsay RM, Heidenheim PA, Nesrallah G, Garg AX, Suri R; Daily Hemodialysis Study Group London Health Sciences Centre: Minutes to recovery after a hemodialysis session: A simple health-related quality of

- life question that is reliable, valid, and sensitive to change. *Clin J Am Soc Nephrol* 1: 952–959, 2006
50. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, Jones DW, Kurtz T, Sheps SG, Roccella EJ: Recommendations for blood pressure measurement in humans and experimental animals: Part 1: Blood pressure measurement in humans: A statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. *Circulation* 111: 697–716, 2005
51. Venables WN, Ripley BD: *Modern Applied Statistics with S*, 4th Ed., New York, Springer, 2002
52. R Core Team: R: A language and environment for statistical computing, Vienna, Austria, R Foundation for Statistical Computing, 2016. Available at: <http://www.R-project.org/>. Accessed April 14, 2016
53. Zeileis A, Kleiber C, Jackman S: Regression models for count data in R. *J Stat Softw* 27: 1–25, 2008
54. Harrell FE Jr: *Regression Modeling Strategies*, Berlin, Springer, 2016

This article contains supplemental material online at <http://jasn.asnjournals.org/lookup/suppl/doi:10.1681/ASN.2017020135/-/DCSupplemental>.

Supplementary Appendix


This appendix has been provided by the authors to give readers additional information the BID Study

Supplement to:
BP in Dialysis: Results of a Pilot Study


TABLE OF CONTENTS

	Page
Appendix 1: Figures	
Supplemental Figure 1: Separation of the standardized predialysis diastolic blood pressure	2
Supplemental Figure 2: Separation of the Home AM Systolic and Diastolic blood pressure	3
Supplemental Figure 3: Mean monthly postdialysis weight in each treatment arm	4
Appendix 2: Tables	
Supplemental Table 1: Number of participants at each geographical center	5
Supplemental Table 2: Reasons for Drop out	6
Supplemental Table 3: Changes in postdialysis weight and interdialytic weight gain by treatment arm	7
Supplemental Table 4: Baseline Characteristics of Participants	8
Supplemental Table 5: Adherence with predialysis standardized blood pressure measurements	9
Supplemental Table 6: Comorbidities and additional baseline characteristics	10
Supplemental Table 7: Adherence with Home Blood Pressure Monitoring	11
Supplemental Table 8: FACIT fatigue scores and recovery times	12
Supplemental Table 9: Physical and mental component scores on Short Form 36 (SF-36)	12
Appendix 3: Eligibility Criteria	13
Appendix 4: BID Study Research Group	14
Appendix 5: Supplemental Methods	15
Appendix 6: Participating Dialysis Clinics	17
Appendix 7: Link to BID Study Protocol	18


Supplemental Figure 1: Separation of Standardized Predialysis Blood Pressure Across Study Arms



Supplemental Figure 2: Separation of the Home AM Blood Pressure Across Study Arms



Supplemental Figure 3: Mean Monthly Postdialysis Weights by Treatment Arm



Supplemental Table 1: Number of patients at each geographical center

Center	Enrolled in Baseline	Dropped out or died before randomization	Randomized
University of New Mexico	98	48	50
Tufts Medical Center	68	37	31
Medical University of South Carolina	50	28	22
University of Pittsburgh	43	30	13
Case Western Reserve University	22	12	10
Total	281	155	126

Supplemental Table 2: Reasons for Drop Out

A total of 281 patients were consented and enrolled in baseline.

Reason	n	Percent
Inability to reach 155 mm Hg despite back-titration or frequent intradialytic or postdialysis hypotension	66	42.6
Judged unlikely to achieve goals due to non-adherence to medications or protocol	9	5.8
Patient, family or nephrologist changed mind due to being uncomfortable with idea of standardized dialysis unit BP or home BP measurements, cardiac MRI, possible back-titration of BP medications or randomization.	45	29
Transfer/anticipated transfer to non-BID unit or in-center nocturnal dialysis	5	3.2
Transplant anticipated	2	1.3
Inability to have MRI	6	3.9
Unwilling/unable to do home BP measurement	1	0.6
Unwilling/unable to do ambulatory BP measurement (not done at Tufts)	5	3.2
Other miscellaneous reasons	16	10.3

Supplemental Table 3. Postdialysis Weight and IDWG

	Intensive Arm (kg) (95% CI)	Standard Arm (kg) (95% CI)	P value Intensive vs. Standard Arm
Postdialysis Weight[^]			
Baseline	78.61 (73.15 to 84.08)	77.89 (72.66 to 83.13)	0.852
End Intervention	79.75 (74.28 to 85.22)	76.84 (71.60 to 82.08)	0.452
Change	1.13 (0.60 to 1.66) P < 0.001	-1.05 (-1.55 to -0.55) P < 0.001	P<0.001
IDWG - 2 Day Interval			
Baseline	2.41 (2.17 to 2.65)	2.42 (2.20 to 2.65)	0.913
End Intervention	2.21 (1.96 to 2.45)	2.18 (1.94 to 2.41)	0.861
Change	-0.20 (-0.3 to -0.15) P < 0.001	-0.25 (-0.35 to -0.15) P < 0.001	0.500
IDWG - 3 Day Interval			
Baseline	3.35 (3.11 to 3.60)	3.31 (3.08 to 3.54)	0.794
End Intervention	3.26 (3.01 to 3.51)	3.12 (2.88 to 3.54)	0.419
Change	-0.10 (-0.23 to 0.04) P = 0.156	-0.19 (-0.32 to 0.06) P = 0.003	0.304

[^]Weights expressed as least square means; 95% CI: 95% confidence intervals

Supplemental Table 4: Baseline Characteristics of Participants

	Randomized (N=126) n (%) or mean $\pm$ SD	Not Randomized (N=155) n (%) or mean $\pm$ SD	p-value	n Randomized / Not Randomized
Age (years)	56.0 $\pm$ 12.8	55.3 $\pm$ 12.9	0.65	126/155
Male	71 (56.4%)	97 (62.6%)	0.29	126/155
Race			0.16	122/121
Native American, Aboriginal Canadian/Alaskan	6 (4.8%)	9 (7.4%)		
Asian	8 (6.4%)	2 (1.7%)		
Black, African American, African	59 (46.8%)	67 (55.4%)		
Native Hawaiian/Pacific Islander	0(0%)	1(0.8%)		
White/Caucasian	50 (39.7%)	42 (34.7%)		
More than one race (multiracial), part N	1 (0.8%)	0(0%)		
Unknown or not reported	2(1.6%)	0(0%)		
Hispanic Ethnicity	44 (34.9%)	21 (17.5%)	0.002	126/120
Cause of ESRD			0.27	122/76
Diabetic Nephropathy	66 (54.1%)	40 (52.6%)		
Hypertensive Nephrosclerosis	39 (32.0%)	18 (23.7%)		
Glomerulonephritis	10 (8.2%)	9 (11.8%)		
Other	7 (5.7%)	9 (11.8%)		
Vascular Access			0.43	126/100
Arteriovenous Graft	22 (17.5%)	13 (13.0%)		
Arteriovenous Fistula	91 (72.2%)	72 (72.0%)		
Central Venous Catheter	13 (10.3%)	15 (15.0%)		
Years on Dialysis (from most recent dialysis start)	3.3 $\pm$ 2.7	3.4 $\pm$ 3.9	0.69	126/155
Last Baseline 2 wk running mean SBP	160.8 $\pm$ 10.9	142.5 $\pm$ 19.1	<0.0001	126/122
Last Baseline 2 wk running mean DBP	80.8 $\pm$ 12.3	77.5 $\pm$ 11.4	0.03	126/122
Treatment Time (minutes)	218.7 $\pm$ 27.8	224.0 $\pm$ 28.0	0.15	126/107
Number of Antihypertensive Medications	2.6 $\pm$ 1.3	2.2 $\pm$ 1.4	0.01	126/119
History of Myocardial Infarction	9 (7.1%)	12 (15.2%)	0.06	126/79
History of Congestive Heart Failure	18 (14.3%)	17 (21.5%)	0.18	126/79
History of CVA	7 (5.6%)	6 (7.6%)	0.56	126/79
History of Atrial Fibrillation	3 (2.4%)	3 (3.8%)	0.56	126/79

P values for race, cause of ESRD and arteriovenous access types are from chi-squared test.

Supplemental Table 5: Adherence with Predialysis Standardized Dialysis Unit Blood Pressure Measurements in the Intensive and Standard Arm

Participants in the Intensive Arm Follow-up Month	# Patients with at least 4 BPs per month /# Expected (%)	# Patients with at least 8 BPs per month /# Expected (%)	# Patients with at least 12 BPs per month /# Expected (%)
1	60/62 (97%)	58/62 (94%)	31/62 (50%)
2	58/60 (97%)	54/60 (90%)	31/60 (52%)
3	58/59 (98%)	57/59 (97%)	38/59 (64%)
4	57/59 (97%)	54/59 (92%)	31/59 (53%)
5	58/59 (98%)	49/59 (83%)	31/59 (53%)
6	54/58 (93%)	48/58 (83%)	27/58 (47%)
7	55/57 (96%)	48/57 (84%)	26/57 (46%)
8	51/56 (91%)	43/56 (77%)	22/56 (39%)
9	47/55 (85%)	40/55 (73%)	16/55 (29%)
10	47/55 (85%)	37/55 (67%)	21/55 (38%)
11	49/55 (89%)	38/55 (69%)	21/55 (38%)
12	45/54 (83%)	35/54 (65%)	16/54 (30%)

Participants in the Standard Arm Follow-up Month	# Patients with at least 4 BPs per month /# Expected (%)	# Patients with at least 8 BPs per month /# Expected (%)	# Patients with at least 12 BPs per month /# Expected (%)
1	60/64 (97%)	54/64 (84%)	41/64 (64%)
2	60/62 (97%)	56/62 (90%)	39/62 (63%)
3	58/62 (94%)	52/62 (84%)	29/62 (47%)
4	53/62 (85%)	51/62 (82%)	30/62 (48%)
5	55/62 (89%)	49/62 (79%)	30/62 (48%)
6	53/61 (87%)	50/61 (83%)	24/61 (39%)
7	49/59 (83%)	36/59 (61%)	20/59 (34%)
8	48/59 (81%)	43/59 (73%)	25/59 (42%)
9	52/58 (90%)	41/58 (71%)	24/58 (41%)
10	46/58 (79%)	37/58 (64%)	16/58 (28%)
11	46/58 (79%)	38/58 (66%)	23/58 (40%)
12	38/57 (67%)	35/57 (61%)	18/57 (32%)

Supplemental Table 6: Comorbidities and Additional Baseline Characteristics

	Randomized Patients (N=126)	Intensive Treatment Arm (N=62)	Standard Treatment Arm (N=64)
Variable	n (%)	n (%)	n (%)
History of Myocardial Infarction	9 (7.1%)	4 (6.5%)	5 (7.8%)
Atrial Fibrillation	3 (2.4%)	2 (3.2%)	1 (1.6%)
Congestive Heart Failure	18 (14.3%)	9 (14.5%)	9 (14.1%)
Peripheral Vascular Disease	9 (7.1%)	5 (8.1%)	4 (6.3%)
Cerebrovascular Disease	7 (5.6%)	4 (6.5%)	3 (4.7%)
COPD	6 (4.8%)	4 (6.5%)	2 (3.1%)
Peptic Ulcer Disease	9 (7.1%)	5 (8.1%)	4 (6.3%)
Diabetes	82 (65.1%)	40 (64.5%)	42 (65.6%)
Hepatitis B surface antigen positive	6 (4.8%)	2 (3.2%)	4 (6.3%)
Hepatitis C positive	11 (8.7%)	6 (9.7%)	5 (7.8%)
HIV	6 (4.8%)	4 (6.5%)	2 (3.1%)
Uses CPAP at night	7 (5.6%)	4 (6.5%)	3 (4.7%)
Legally blind	2 (1.6%)	2 (3.2%)	0 (0.0%)
Current Smoker	18 (14.3%)	6 (9.7%)	12 (18.8%)
Past history of smoking	43 (34.1%)	24 (38.7%)	19 (29.7%)
Current alcohol abuse	5 (4.0%)	2 (3.2%)	3 (4.7%)
History of alcohol abuse	18 (14.3%)	9 (14.5%)	9 (14.1%)
History of illicit drug use	18 (14.3%)	8 (12.9%)	10 (15.6%)
One or more ICU or CCU admission in the past year	21 (16.6%)	17 (27.4%)	4 (6.3%)
Patient medically ineligible for transplant	9 (7.1%)	6 (9.7%)	3 (4.7%)
Patient is currently on cadaveric transplant waiting list	48 (38.1%)	24 (38.7%)	24 (37.5%)
History of kidney transplant	8 (6.3%)	4 (6.5%)	4 (6.3%)
Patient uses a wheelchair to move around	7 (5.6%)	5 (8.1%)	2 (3.1%)

Supplemental Table 7: Adherence with Home Blood Pressure Monitoring

Follow-up Month	Number of participants with ≥ 1 home BP per month divided by number expected (%)	Number of participants with ≥ 4 home BPs per month divided by number expected (%)
1	103/126 (82%)	45/126 (36%)
2	97/122 (80%)	38/122 (31%)
3	87/121 (72%)	34/121 (28%)
4	88/121 (73%)	40/121 (33%)
5	90/121 (74%)	30/121 (25%)
6	87/119 (73%)	41/119 (34%)
7	77/116 (66%)	32/116 (28%)
8	78/115 (68%)	29/115 (25%)
9	72/113 (64%)	29/113 (26%)
10	73/113 (65%)	28/113 (25%)
11	77/113 (68%)	28/113 (25%)
12	69/111 (62%)	24/111 (22%)

Supplemental Table 8: FACIT fatigue scores and recovery times

Restricted to patients with both baseline and follow-up measures

	Intensive Treatment Arm	Standard Treatment Arm	P value
FACIT mean $\pm$SD	(N=53)	(N=52)	t-test
Baseline	31.0 $\pm$ 12.9	29.2 $\pm$ 12.0	
Follow-up	29.2 $\pm$ 12.2	28.0 $\pm$ 11.7	
Change	-1.8 $\pm$ 9.0	-1.3 $\pm$ 8.8	0.76
Recovery Question median (IQR)	(N=51)	(N=45)	Wilcoxon
Baseline	2.0 (1.0, 12.0)	2.0 (1.0, 6.0)	
Follow-up	3.0 (2.0, 9.0)	2.0 (1.0, 4.0)	
Change	0.0 (-1.0, 1.5)	0.0 (-1.0, 1.0)	0.69

Supplemental Table 9: Physical and mental component scores on Short Form 36 (SF-36)

			Observed Data Mean $\pm$ SD		Main secondary analyses, controlling for baseline value and clinical centers			
Outcome	Treatment	N ^a				Adjusted change from baseline Mean $\pm$ SE	Treatment comparison of change: Standard vs. Intensive (95% CI)	P value
			Baseline	Follow-up	Change from baseline to follow-up			
PCS	Standard	51	40.0 $\pm$ 8.1	39.8 $\pm$ 8.1	-0.2 $\pm$ 5.2	-0.07 $\pm$ 0.95	-1.7	0.20
	Intensive	51	39.8 $\pm$ 10.0	38.3 $\pm$ 10.6	-1.6 $\pm$ 8.6	-1.8 $\pm$ 1.0	(-4.3, 0.9)	
MCS	Standard	51	45.4 $\pm$ 9.8	44.1 $\pm$ 10.3	-1.3 $\pm$ 9.9	-1.5 $\pm$ 1.4	+2.2	0.22
	Intensive	51	45.5 $\pm$ 11.5	46.3 $\pm$ 10.7	+0.8 $\pm$ 11.3	+0.7 $\pm$ 1.4	(-1.3, 5.7)	

PCS, physical component score; MCS, mental component score

^a Number of randomized patients providing both baseline and follow-up measurements for the respective outcomes

Appendix 3: Eligibility Criteria

- A. Inclusion criteria
 - 1. For entry into baseline period: 2-week average routine dialysis unit SBP > 155 mm Hg on antihypertensive medications or < 155 mm Hg on ≥ 1 antihypertensive medications
For randomization: 2-week average standardized dialysis unit SBP ≥ 155 mm Hg
 - 2. Age ≥ 18 years
 - 3. Thrice weekly HD for ≥ 90 days
 - 4. Able to obtain and record weekly home BP measurements or has a partner willing to do this
- B. Exclusion criteria
 - 1. Two-week average, predialysis midweek routine dialysis unit SBP ≥ 180 mm Hg on maximal doses of ≥ 4 AHT agents
 - 2. Inability to measure SBP in an upper arm
 - 3. History of intra- or post-dialysis hypotension (routine dialysis unit SBP < 90 mm Hg) within the past 2 weeks or requiring hospitalization, emergency room visit or the use of midodrine in the past month
 - 4. Unscheduled dialysis treatments for congestive heart failure within the past 3 months
 - 5. Acute myocardial infarction, unstable angina, stroke or transient ischemic attack in the past 3 months
 - 6. Known history of aortic stenosis (aortic valve area < 1 cm²)
 - 7. Known history of severe carotid artery stenosis (> 70% stenosis)
 - 8. Known abdominal aortic aneurysm > 5 cm in diameter or thoracic aortic aneurysm of any diameter
 - 9. Arm circumference > 60 cm which precludes measuring blood pressure with the extra large blood pressure cuff or arm circumference < 16 cm, which precludes measuring blood pressure with the small adult blood pressure cuff.
 - 10. Life expectancy < 1 year
 - 11. Living donor, kidney transplant or switch to peritoneal dialysis scheduled within the next year
 - 12. Significant cognitive impairment
 - 13. spKt/V ≤ 1.2 in the past 2 months
 - 14. Active liver disease
 - 15. Alcohol or substance abuse in the past year
 - 16. Contraindication to cardiac MRI
 - 17. Current or planned pregnancy
 - 18. Unwillingness to consent to pregnancy test and use of two forms of contraception if of childbearing potential
 - 19. Suspected poor adherence to study protocol
 - 20. Incarcerated
 - 21. Significant concern about the study expressed by participant's physician
 - 22. Participation in another intervention study
 - 23. Unable to speak or understand English, Spanish, Cantonese or Mandarin
 - 24. Plan to relocate within a year

Appendix 4: BID Study Research Group

Steering Committee: Philip Zager (Principal Investigator, New Mexico Clinic Centers Network), Dana Miskulin (Principal Investigator, Massachusetts Clinic Centers Network), Jennifer Gassman (Principal Investigator, Data Coordinating Center), John Kusek (Program Officer, National Institute of Health), David Ploth (Principal Investigator, South Carolina Clinic Centers Network), Manisha Jhamb (Principal Investigator, Pittsburgh Clinic Centers Network), Mahboob Rahman (Principal Investigator, Ohio Clinic Centers Network).

Program Office: National Institutes of Health, Bethesda, Maryland: John Kusek (Program Officer), Barbara Woynarowska (Scientific Review Administrator), Charlette Kenley (Grants Management Specialist).

BID Clinical Center Network: University of New Mexico, Albuquerque, NM: Philip Zager (Principal Investigator), Antonia Harford (Co-Principal Investigator), Ed Bedrick (Co-Principal Investigator), Bruce Horowitz (Co-Principal Investigator), Mark Unruh (Co-Principal Investigator), Susan Paine (Data Manager), Ronald Schrader (Biostatistician), Rodrigo Madero (Study Coordinator), Christina Marquez (Study Coordinator), Jose Vega (Study Coordinator), Nicole (Margaret) Trujillo (Study Coordinator), Serena Cumber (Grant Administrator), Leslie Firkins (Assistant Grant Administrator), Ambreen Gul (Investigator) ; **Tufts Medical Center, Boston, MA:** Dana Miskulin (Principal Investigator), Andrew Levey (Co-Principal Investigator), Fadi Obeid (Study Coordinator), Shana M. Haynes (Study Coordinator), Poonhar Poon (Study Coordinator), Katie Knipscher (Study Coordinator); **Medical University of South Carolina, Charleston, SC:** David Ploth (Principal Investigator), Milos Budisavljevic (Co-Principal Investigator), Roberto Pisoni (Co-Principal Investigator), Deborah Brooks (Co-Principal Investigator), Judy Widlowski (Junior Study Coordinator), Caroline Counts (Study Coordinator), Kimberly Harrelson (Study Coordinator); **University of Pittsburgh Medical Center, Pittsburgh, PA:** Manisha Jhamb (Principal Investigator), Ameet Karambelkar (Co-Principal Investigator), Missy Weimer (Study Coordinator), Stacy Stull (Study Coordinator); **Case Western Reserve University, Cleveland, OH:** Mahboob Rahman (Principal Investigator), Lavinia Negrea (Co-Principal Investigator), Peter DeOreo (Co-Principal Investigator), Vicki Donley (Study Coordinator).

BID Data Coordinating Center: Cleveland Clinic, Cleveland, OH: Jennifer Gassman (Principal Investigator), Karen Brittain (Study Coordinator), Cynthia A. Kendrick (Statistical Programmer), Sam (Robert) Butler (Biostatistician), Jack MacKrell (System Analyst), Susan Sherer (Study Coordinator), Kimberly Wiggins (System Analyst).

BID Drug Distribution Center: DCI Pharmacy, Nashville, TN: R. Michael Dickenson (Director of Pharmacy)

BID MRI Reading Center: Brigham and Women's Hospital, Boston, MA: Raymond Kwong (Principal Investigator).

BID MRI Personnel: University of New Mexico, Albuquerque, NM: Loren Ketai (Radiologist), Jane Potter (Staff); **Massachusetts Clinic Centers Network:** Raymond Kwong (Radiologist); **Medical University of South Carolina, Charleston, SC:** Marcy Brown (MRI Technician), Holly Oliver (MRI Technician); **University of Pittsburgh Medical Center, Pittsburgh, PA:** Ty Bae (Radiologist), Tom Porter

(MRI Technician); **Case Western Reserve University, Cleveland, OH:** Mark Clampitt (Radiology Chief Technician).

BID Central Laboratory: DCI Laboratory, Nashville, TN: Scott Hall (Medical Director), *Peggy Armes (Laboratory Manager), Beth Kammer (Laboratory Administrator), Doreen Moss (Chemistry Supervisor), Connie Dutton (Manager of Accessioning and Logistics)

BID Sub-Committees: Blood Pressure Committee: Manisha Jhamb, Dana Miskulin, Roberto Pisoni, Karen Brittain, Cynthia Kendrick; **Data and Lab Quality Committee:** Jennifer Gassman, Dana Miskulin, Antonia Harford, Susan Paine, Bruce Horowitz, Joan Alster; **Executive Committee, Publications and Ancillary Studies Committee and Dispute Resolution Committee:** John Kusek, Jennifer Gassman, Dana Miskulin, Philip Zager; **Forms Committee:** Dana Miskulin, Karen Brittain, Jennifer Gassman, Susan Paine, Susan Shere; **Forms Review Committee:** Philip Zager, Antonia Harford, Bruce Horowitz, Mark Unruh, Susan Paine, Dana Miskulin, Andrew Levey, David Ploth, Milos Budisavljevic, Roberto Pisoni, Manisha Jhamb, Ajay Singh, Karen Brittain, Jennifer Gassman, Jack MacKrell, Susan Sherer, Kimberly Wiggins; **Outcomes Review Committee:** Andrew Levey, Ajay Singh, Susan Paine, Serena Cumber, Karen Brittain, Jennifer Gassman, Jack MacKrell, Susan Sherer; **Quality Control Committee:** Jennifer Gassman, Dana Miskulin, Susan Paine, Karen Brittain, Philip Zager, Roberto Pisoni, Manisha Jhamb; **Study Coordinators Committee:** Susan Paine, Serena Cumber, Nicole (Margaret) Trujillo, Christina Marquez, Judy Widlowski, Manisha Jhamb, Missy Weimer, Vicki Donley, Renee (Katherine) Carter, Victoria Rodriguez, Karen Brittain, , Jennifer Gassman, Susan Sherer.

BID Data Safety Monitoring Board: Thomas Hostetter (Chair), Rajiv Agarwal, Alfred Cheung, Vernon Chinchilli, Adeera Levin, Nathan Levin, Donald Stablein.

BID Information Technology: DCI Information Technology, Chicago, IL: Pramen Appasamy (Clinical Operations Application Manager), Robert Kroll (Software Developer).

Acknowledgements

The Blood Pressure in Dialysis Trial is funded with Federal funds from the National Institutes of Health (NIH), including the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under Contract Numbers R01DK083424. It was also supported in a cost-share agreement with funding, resources and use of facilities through Dialysis Clinic Inc. [ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT01421771) Identifier: NCT01421771

We are grateful for the support extended to this study by Ed Attrill (DCI, President), Keith Johnson (DCI, Chairman of the Board), and Douglas Johnson (DCI, Vice-Chairman of the Board)

Appendix 5: Supplemental Methods

Cardiac Magnetic Resonance Imaging

A secondary outcome of the BID Study was to determine differences in the changes in LVM as assessed by Cardiac Magnetic Resonance Imaging (MRI) between the intensive versus the standard treatment arm. Cardiac MRIs were performed utilizing either 1.5 or 3.0 Tesla (T) imaging systems at the end of the baseline period and again at the end of the 12-month intervention. They were performed on a non-dialysis day that did not encompass a 3-day interdialytic period. Left ventricular myocardial mass (LVM) was measured using a standardized protocol. All MRI technicians at each site were by the core lab located at Brigham and Women's Hospital. MRIs were read side-by-side by a single observer at the core lab who was blinded to the randomization. LVM was calculated excluding papillary muscle. Reference values for normal LVM gender were obtained from Kawel-Boehm et al²⁸.

Methods: Back-titration of Medications During Baseline

If a participant's SBP was <155 mm Hg and they were receiving antihypertensive medication(s), the dose of one medication at a time was decreased by half or discontinued and the participant was observed for 2 weeks. Further dose reductions were undertaken until the SBP was ≥ 155 mm Hg or all antihypertensive medications had been discontinued. BP was measured prior to each dialysis treatment and reviewed at weekly study visits, as were symptoms and interim adverse events.

Appendix 6: Participating Dialysis Centers

Dialysis Unit

DCI Albuquerque
DCI Albuquerque East
DCI Rio Rancho
DCI Grants
DCI Albuquerque South
DCI Boston
DCI Somerville
DaVita Boston
DCI Faulkner
DCI Azalea Place
DCI James Island
DCI East Cooper
DCI Magnolia Court
DCI West Ashley
DCI Oakland
DCI Banksville
DCI Point Breeze
DCI North Hills
CDC East
CDC Shaker Heights

Location

Albuquerque, NM
Albuquerque, NM
Rio Rancho, NM
Grants, NM
Albuquerque, NM
Boston, MA
Somerville, MA
Boston, MA
Jamaica Plain, MA
North Charleston, SC
Charleston, SC
Mt. Pleasant, SC
Charleston, SC
Charleston, SC
Pittsburgh, PA
Pittsburgh, PA
Pittsburgh, PA
Pittsburgh, PA
Cleveland, OH
Shaker Heights, OH

Appendix 7: BID Study Protocol

Accessible at

<http://ghsapps.ccf.org/bid/protocol/Protocol.pdf>

Design of the Blood Pressure in Dialysis (BID) Pilot Study

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647384/>

SIGNIFICANCE STATEMENT

The SPRINT trial demonstrated benefit of intensive control of blood pressure (BP) in high-risk, non-dialysis patients, but the optimal BP in hemodialysis patients is uncertain due to the lack of randomized clinical trial (RCT) data. We performed a pilot RCT of intensive versus standard BP control to assess the feasibility and safety of a full-scale RCT. During months 4-12 the average difference in systolic BP across arms was 12.9 mm Hg. Although not powered for outcomes, we identified a potential safety signal: hospitalizations, vascular access thromboses, and intradialytic hypotension were more frequent in the intensive arm. These results support the need for a full-scale study to determine definitely the effects of intensive BP control on clinical outcomes in hemodialysis patients.